顺铂-羟基磷灰石-壳聚糖缓释微球小鼠体内安全性评价.docVIP

  顺铂-羟基磷灰石-壳聚糖缓释微球小鼠体内 安全性评价# 冯卫1，付莉2，刘建国1** 5 10 15 20 25 30 35 40 45 （1. 吉林大学第一医院，长春 130021； 2. 吉林大学第二医院，长春 130021） 摘要：目的：采用腹腔内给药的方式，评估了 DDP-HAP-CS 缓释微球在小鼠体内的安全性。 方法：随机将小鼠分为对照组、DDP 组和 DDP-HAP-CS 组，每组 10 只，采用腹腔注射的方式 给药，对照组注射 PBS（0.5ml/只）、DDP 组注射 DDP（3mg/kg）、DDP-HAP-CS 组注射 DDP-HAP-CS 微粒（微粒中 DDP 的剂量为 3mg/kg）。每 3 天给药一次，共 5 次，第 5 次给药后 3 天终止 实验。评价指标包括：小鼠的一般状态、进食、活动等情况；监测小鼠体重；实验终止时取 小鼠眶静脉血，选择 ALT、AST、TP、ALB、BUN 和 Cr 六项指标作为评价各组小鼠肝、肾功能 的标准，血常规作为药物对骨髓抑制程度的评价标准；取心脏、肝脏和肾脏进行组织病理学 观察。结果：DDP 组小鼠一般状态和体重均较 DDP-HAP-CS 组差。DDP 组和 DDP-HAP-CS 组进 行比较，DDP 组的 ALT、AST 和 Cr 三项指标均明显高于 DDP-HAP-CS 组，具有统计学差异， P0.05；DDP-HAP-CS 组小鼠的骨髓抑制程度较轻；DDP-HAP-CS 组小鼠的心脏、肾脏形态学 改变较 DDP 组程度轻，肝脏未见到淋巴细胞的浸润。结论：经腹腔注射 DDP-HAP-CS 缓释微 球对机体正常组织的毒副作用小于经腹腔注射同等剂量的游离 DDP。 关键词：外科学；顺铂；纳米；羟基磷灰石 中图分类号：R738.1 Safety Evaluation of Cisplatin-Hydroxyapatite–Chitosan Sustained Release Microspheres in mice Feng Wei1, Fu Li2, Liu Jianguo1 (1. the First Hospital of Jilin University, ChangChun 130021; 2. the Second Hospital of Jilin University, ChangChun 130021) Abstract: Objective: To evaluation of safety of DDP-HAP-CS sustained release microsphere in mice. Methods: The healthy BALB/C mice were divided into three groups at random, Control group: injection of 0.5ml PBS per mouse; DDP group: injection of DDP of 3mg/kg per mouse; DDP-HAP-CS group: injection of DDP-HAP-CS sustained release microsphere in which containing DDP of 3mg/kg per mouse. Each mouse was treated with intraperitoneal injection every three days for five times. The changes of general condition and weight of mouse were observed throughout the experiment. At the end of experiment，the hepatic and renal functions and CBC were analyzed by detection of orbital venous blood，the slices of heart、hepatic and renal tissues were stained with HE and the histopathologic observation was manipulated. Results: The general condition was well in control group and in DDP-HAP-CS group. The average weight of mice was slowly rising in control group and was slowly descending in DDP-HAP-C